Sleep Medications and Cardiovascular Safety

Sleep Medications and Cardiovascular Safety

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history and concurrent conditions. Always consult qualified healthcare providers for medical decisions. Never delay seeking medical care based on content you’ve read. If experiencing a medical emergency, seek immediate medical attention.

These articles provide education to enhance your healthcare partnership. All treatment decisions should involve your healthcare team. Use this knowledge to have informed discussions, not replace medical care.

In Brief: For chronic insomnia, cognitive behavioral therapy is the first-line treatment, not medication. That is the position of the American College of Physicians and the American Academy of Sleep Medicine, based on durable benefit without drug-related harms. Medications still have a role for short-term or bridge use, but their most consequential harms are often indirect. Falls, nocturnal hypoxemia, orthostatic hypotension, QT prolongation, and metabolic effects usually matter more in cardiac patients than any direct cardiac action. Sleep is a cardiovascular exposure repeated night after night, and medications should protect that exposure, not compromise it.

For chronic insomnia, cognitive behavioral therapy for insomnia is the standard first-line treatment, not medication. This is not a preference or a piece of lifestyle advice. It is the position of the American College of Physicians, the American Academy of Sleep Medicine, and European sleep societies. The evidence shows this therapy matches medications in the short term and produces superior, sustained benefit long term without medication-related harms.(1, 2) Medications still have a role. They can be appropriate for short-term insomnia during acute stress, as a bridge while behavioral treatment is started, when that treatment is unavailable, or when insomnia persists despite it. The question is not whether sleep medications ever make sense, but how carefully the tradeoffs are managed, particularly in people with cardiovascular disease. These drugs do not act in isolation, because they can influence autonomic tone, blood pressure, breathing during sleep, balance, cognition, and metabolism, systems often already vulnerable in cardiac patients. In that context the downstream risks of sedation, including falls, nocturnal hypoxemia, and orthostatic hypotension, frequently matter more than any direct cardiac effect. Sleep is a cardiovascular exposure repeated night after night, and medications should protect that exposure, not compromise it.

What CBT-I Is, and Why It Comes First

Cognitive behavioral therapy for insomnia is a structured, evidence-based treatment that targets the mechanisms maintaining insomnia: conditioned arousal, fragmented sleep opportunity, irregular timing, and unhelpful behaviors around sleep. It typically combines sleep restriction to consolidate sleep opportunity, stimulus control to re-link the bed with sleep rather than wakefulness, cognitive work on sleep-related anxiety, and circadian stabilization. Unlike medications, it improves sleep without impairing respiration or balance, does not increase fall risk, does not worsen sleep apnea, and keeps working after treatment ends. For patients with cardiovascular disease those advantages are concrete, because avoiding sedation-related falls on anticoagulation, avoiding worsened nocturnal hypoxemia in sleep apnea, and preserving overnight autonomic recovery all matter. Access remains uneven, since the therapy can be delivered in person or through validated digital programs, and when it is available it should be tried before long-term medication use. When it is not available, medications may be used with explicit attention to safety and planned reassessment.

General Principles When Medications Are Used

When a sleep medication is prescribed thoughtfully, a few themes recur. Doses are kept low, escalation is slow, and reassessment is planned rather than deferred indefinitely. Contributors such as sleep apnea, depression, pain, medication timing, and substance use are addressed in parallel. In cardiovascular patients, particular attention goes to fall risk, orthostatic symptoms, respiratory vulnerability during sleep, QT prolongation, and metabolic effects. This is not simply extra caution, because the most consequential harms of sleep medications are often indirect, and those indirect harms carry higher stakes in cardiac populations.

Benzodiazepines

Benzodiazepines such as temazepam, triazolam, and flurazepam enhance GABA activity to produce sedation, anxiolysis, and muscle relaxation. They are effective for both falling asleep and staying asleep, but they carry substantial liabilities. In patients with cardiovascular disease the main concerns are falls, especially on anticoagulation,(4) respiratory depression in the presence of sleep apnea or heart failure, and dependence with chronic use.(3, 6) Observational studies associate benzodiazepines with increased mortality, although confounding remains an important limitation.(5) On balance they are effective but high-risk, and they are generally not appropriate for chronic insomnia in cardiac patients.

Non-Benzodiazepine Z-Drugs

Zolpidem, zaleplon, and eszopiclone act at the GABA receptor with greater selectivity. They are widely prescribed and tend to cause fewer cognitive and muscle-relaxant effects than benzodiazepines, though many of the risks overlap.(7) For cardiovascular patients, fall risk remains the dominant concern, particularly in older adults and those on anticoagulation.(8) Complex sleep behaviors such as sleepwalking and sleep-driving are uncommon but potentially dangerous, and are most associated with zolpidem.(9) These agents are reasonable for short-term use in selected patients, but they are not benign and are rarely ideal as long-term therapy.

Dual Orexin Receptor Antagonists

Suvorexant, lemborexant, and daridorexant block orexin, a neuropeptide that promotes wakefulness, so they reduce wake drive rather than inducing sedation. From a cardiovascular perspective they are notable for minimal respiratory depression, no meaningful blood-pressure effect, and potentially lower fall risk than the GABA-active drugs. They may be especially attractive in patients with sleep apnea or high fall risk, though long-term cardiovascular outcome data are still limited.(10, 11, 12) These are newer brand-name medications, so coverage varies, prior authorization is common, and out-of-pocket cost can be substantial, which is a practical rather than a physiologic limitation. The profile is promising where respiratory or fall risk is a concern, with cost and limited long-term data as the main constraints.

Melatonin Receptor Agonists

Ramelteon is a prescription melatonin receptor agonist that modestly improves sleep onset.(13) It is not a controlled substance and lacks the respiratory and fall liabilities of the GABA-active hypnotics, though it has not been shown to improve cardiovascular outcomes. Its limitation is efficacy, since it is often insufficient for severe insomnia. From a cardiovascular standpoint it is among the safest options, with a modest average benefit.

Sedating Antidepressants

Trazodone is widely used off-label, and its most important cardiovascular issue is orthostatic hypotension, which can lead to falls and is a critical concern in patients on anticoagulation, with QT prolongation possible at higher doses.(14) Mirtazapine can improve sleep in depressed patients but often causes weight gain, which is problematic in cardiometabolic disease. Low-dose doxepin, at 3 to 6 mg, is approved for sleep maintenance and at these doses lacks the cardiotoxicity associated with higher-dose tricyclics.(15) Other tricyclics should generally be avoided, given the dose-related risk of sudden cardiac death seen with the broader cyclic-antidepressant class.(16)

Antihistamines

Diphenhydramine and doxylamine produce sedation but lose effectiveness quickly. Their anticholinergic effects, next-day impairment, and association with cognitive decline make them poor choices for regular use, particularly in older adults with cardiovascular disease.(17, 18)

Antipsychotics and Gabapentinoids

Sedating antipsychotics carry unacceptable metabolic and QT risk when used for insomnia alone.(19) Gabapentinoids may help when pain or restless legs are present, but they can worsen edema and respiratory suppression, especially in heart failure.

Cardiovascular Safety at a Glance

When Medications Make Sense

Medications may be appropriate for acute insomnia, as temporary bridge therapy, when behavioral treatment is unavailable, or when a comorbid condition justifies their use. When they are used, they should be paired with an explicit plan for reassessment rather than open-ended continuation.

Common Assumptions vs. the Physiology

The Bottom Line

Sleep medications are not first-line therapy for chronic insomnia; cognitive behavioral therapy is. When medications are used, especially in patients with cardiovascular disease, the central question is not whether a drug helps sleep but what risks it introduces in this particular patient. Falls, nocturnal hypoxemia, orthostatic hypotension, QT prolongation, and metabolic effects often matter more than direct cardiac pharmacology. The safest options are those that improve sleep without undermining the cardiovascular recovery that sleep is meant to provide. Sleep is a cardiovascular exposure repeated night after night, year after year, and medications should protect that exposure, not compromise it.

What Comes Next

With screening, behavioral treatment, device therapy, and careful medication use now covered, the series turns to integration: how these pieces fit together into a coherent, heart-protective approach to sleep that holds up across a lifetime.

Key Terms

CBT-I (cognitive behavioral therapy for insomnia): a structured therapy that targets the behaviors and arousal patterns maintaining insomnia, and the recommended first-line treatment for chronic insomnia.

DORAs (dual orexin receptor antagonists): a medication class that reduces wake drive by blocking orexin signaling.

QT prolongation: lengthening of ventricular repolarization that raises the risk of a dangerous rhythm called torsades de pointes in vulnerable settings.

Orthostatic hypotension: a drop in blood pressure on standing that can cause dizziness and falls.

Rebound insomnia: a worsening of sleep after stopping a sedative-hypnotic, often transient but sometimes clinically significant.

References

1. Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD; Clinical Guidelines Committee of the American College of Physicians. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;165(2):125-133. doi:10.7326/M15-2175.
2. Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307-349. doi:10.5664/jcsm.6470. PMID: 27998379.
3. Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ. 2000;162(2):225-233. PMID: 10674059.
4. Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med. 2009;169(21):1952-1960. doi:10.1001/archinternmed.2009.357. PMID: 19933955.
5. Weich S, Pearce HL, Croft P, et al. Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. BMJ. 2014;348:g1996. doi:10.1136/bmj.g1996. PMID: 24647164.
6. Lader M. Benzodiazepines revisited — will we ever learn? Addiction. 2011;106(12):2086-2109. doi:10.1111/j.1360-0443.2011.03563.x.
7. Huedo-Medina TB, Kirsch I, Middlemass J, Klonizakis M, Siriwardena AN. Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ. 2012;345:e8343. doi:10.1136/bmj.e8343.
8. Tom SE, Wickwire EM, Park Y, Albrecht JS. Nonbenzodiazepine sedative hypnotics and risk of fall-related injury. Sleep. 2016;39(5):1009-1014. doi:10.5665/sleep.5742.
9. Farkas RH, Unger EF, Temple R. Zolpidem and driving impairment — identifying persons at risk. N Engl J Med. 2013;369(8):689-691. doi:10.1056/NEJMp1307972.
10. Herring WJ, Connor KM, Ivgy-May N, et al. Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials. Biol Psychiatry. 2016;79(2):136-148. PMID: 25526970.
11. Kärppä M, Yardley J, Pinner K, et al. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2. Sleep. 2020;43(9):zsaa123. doi:10.1093/sleep/zsaa123.
12. Sun H, Palcza J, Card D, et al. Effects of suvorexant, an orexin receptor antagonist, on respiration during sleep in patients with obstructive sleep apnea. J Clin Sleep Med. 2016;12(1):9-17. doi:10.5664/jcsm.5382.
13. Liu J, Wang LN. Ramelteon in the treatment of chronic insomnia: systematic review and meta-analysis. Int J Clin Pract. 2012;66(9):867-873. doi:10.1111/j.1742-1241.2012.02987.x. PMID: 22897464.
14. Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry. 2005;66(4):469-476. doi:10.4088/jcp.v66n0409. PMID: 15816789.
15. Krystal AD, Lankford A, Durrence HH, et al. Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep. 2011;34(10):1433-1442. doi:10.5665/SLEEP.1294. PMID: 21966075.
16. Ray WA, Meredith S, Thapa PB, Hall K, Murray KT. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther. 2004;75(3):234-241. doi:10.1016/j.clpt.2003.09.019. PMID: 15001975.
17. Glass JR, Sproule BA, Herrmann N, Busto UE. Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: a randomized, placebo-controlled trial. J Clin Psychopharmacol. 2008;28(2):182-188. doi:10.1097/JCP.0b013e31816a9e4f. PMID: 18344728.
18. Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401-407. doi:10.1001/jamainternmed.2014.7663. PMID: 25621434.
19. Hasnain M, Vieweg WVR. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. CNS Drugs. 2014;28(10):887-920. doi:10.1007/s40263-014-0196-9. PMID: 25168784.

HeartBuddi • Your heart. Own it.